-
Founded in:
1996-04-09 -
Country:
China -
Address:
No. 25, Hongyuan Road, Xiqing Economic Development Zone, Tianjin -
Tax NO.:
911201112389964770 -
Registered Funds:
30 million yuan -
Website:
-
Email:
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| BREVISCAPIN |
Extract from the above information
More
Extract from the above information |
116122-36-2 | 0 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Iron-dextran |
This product is a complex of dextran and iron, which is soluble iron. Iron is a component of hemoglobin in red blood cells. When iron is deficient, the amount of hemoglobin synthesized by red blood cells decreases, causing the red blood cells to become smaller and their oxygen-carrying capacity to decrease, resulting in iron deficiency anemia. Oral administration of this product can supplement iron and correct iron deficiency anemia.
More
This product is a complex of dextran and iron, which is soluble iron. Iron is a component of hemoglobin in red blood cells. When iron is deficient, the amount of hemoglobin synthesized by red blood cells decreases, causing the red blood cells to become smaller and their oxygen-carrying capacity to decrease, resulting in iron deficiency anemia. Oral administration of this product can supplement iron and correct iron deficiency anemia. |
9004-66-4 | 14 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Telmisartan |
Telmisartan is a specific angiotensin II receptor (ATⅠ type) antagonist that binds to the ATⅠ receptor subtype with high affinity, has no agonist effect, and selectively binds for a long time. It does not inhibit human plasma renin, ion channels or angiotensin converting enzyme II, and does not affect the action of bradykinin. 80 mg can almost completely inhibit the increase in blood pressure caused by angiotensin II, and the antihypertensive effect lasts for more than 24 hours. It takes effect within 3 hours after the first dose and reaches the maximum antihypertensive effect in 4 weeks. There is no rebound hypertension after sudden discontinuation of the drug. The incidence of dry cough in clinical trials is lower than that in the angiotensin converting enzyme inhibitor treatment group.
More
Telmisartan is a specific angiotensin II receptor (ATⅠ type) antagonist that binds to the ATⅠ receptor subtype with high affinity, has no agonist effect, and selectively binds for a long time. It does not inhibit human plasma renin, ion channels or angiotensin converting enzyme II, and does not affect the action of bradykinin. 80 mg can almost completely inhibit the increase in blood pressure caused by angiotensin II, and the antihypertensive effect lasts for more than 24 hours. It takes effect within 3 hours after the first dose and reaches the maximum antihypertensive effect in 4 weeks. There is no rebound hypertension after sudden discontinuation of the drug. The incidence of dry cough in clinical trials is lower than that in the angiotensin converting enzyme inhibitor treatment group. |
144701-48-4 | 109 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Simvastatin |
This product is a methylhydroxyglutaryl coenzyme A (HMG-COA) reductase inhibitor, which inhibits the synthesis of endogenous cholesterol and is a blood lipid regulator. Literature data show that it can reduce the cholesterol (TC) content in the serum, liver, and aorta of hyperlipidemia rabbits, and reduce the levels of very low density lipoprotein cholesterol (VLDL-C) and low density lipoprotein cholesterol (LDL-C).
More
This product is a methylhydroxyglutaryl coenzyme A (HMG-COA) reductase inhibitor, which inhibits the synthesis of endogenous cholesterol and is a blood lipid regulator. Literature data show that it can reduce the cholesterol (TC) content in the serum, liver, and aorta of hyperlipidemia rabbits, and reduce the levels of very low density lipoprotein cholesterol (VLDL-C) and low density lipoprotein cholesterol (LDL-C). |
79902-63-9 | 63 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Fluconazole |
Fluconazole is a new triazole antifungal drug with a broad-spectrum antifungal effect. It can selectively inhibit the sterol synthesis of fungi. It is effective against Candida infection, Cryptococcus neoformans infection, Malassezia sacchariflora, Microsporum, Trichophyton, Epidermophyton, Blastomyces dermatitidis, Coccidioides immitis, Histoplasma capsulatum, Peyer's Chromatid, and Cladosporium carinii. It has a highly selective inhibitory effect on fungal cytochrome p-450-dependent enzymes.
More
Fluconazole is a new triazole antifungal drug with a broad-spectrum antifungal effect. It can selectively inhibit the sterol synthesis of fungi. It is effective against Candida infection, Cryptococcus neoformans infection, Malassezia sacchariflora, Microsporum, Trichophyton, Epidermophyton, Blastomyces dermatitidis, Coccidioides immitis, Histoplasma capsulatum, Peyer's Chromatid, and Cladosporium carinii. It has a highly selective inhibitory effect on fungal cytochrome p-450-dependent enzymes. |
86386-73-4 | 69 |